MedTrace Logo

Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

NCT02453581 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-08-17

Study results available
· View outcomes & findings →

Summary

A single centre, open, controlled study using Blood Stage Plasmodium falciparum challenge inoculum (BSPC) as a model to assess the effectiveness of three dose levels of the experimental anti-malarial product, OZ439.

Conditions

Interventions

DRUG

OZ439

OZ439 Powder for Oral Suspension

Sponsors & Collaborators

  • Queensland Institute of Medical Research

    collaborator OTHER

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • James McCarthy, Pr · Q-Pharm Pty Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453581 on ClinicalTrials.gov